Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 375 of 3499 entries
View as:

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00005976 Org: User:
Start: 05/31/00 End: 04/30/07 Due: 04/30/08

Susceptibility to Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00004565 Org: User:
Start: 02/08/00 End: 05/04/12 Due: 05/04/13

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00040352 Org: User:
Start: 07/01/02 End: - Due: -

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00538187 Org: User:
Start: 12/31/07 End: - Due: -

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06980038 Org: User:
Start: 10/31/25 End: 05/01/27 Due: 05/01/28

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT01005654 Org: User:
Start: 10/07/09 End: - Due: -

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06654037 Org: User:
Start: 04/18/25 End: 01/12/26 Due: 01/12/27

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Phase: N/A Priority: Normal
NCT ID: NCT01647165 Org: User:
Start: 07/11/12 End: 06/26/15 Due: 06/26/16

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

Phase: N/A Priority: Normal
NCT ID: NCT00026728 Org: User:
Start: 02/28/01 End: 12/31/05 Due: 12/31/06

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04160195 Org: User:
Start: 12/20/19 End: 06/11/21 Due: 06/11/22

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00445549 Org: User:
Start: 01/31/07 End: 10/31/09 Due: 10/31/10

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01457131 Org: User:
Start: 10/06/11 End: 08/07/13 Due: 08/07/14

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT04444921 Org: User:
Start: 11/17/20 End: 03/31/26 Due: 03/31/27

Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00629226 Org: User:
Start: 10/31/07 End: - Due: -

Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06965114 Org: User:
Start: 09/30/25 End: 03/01/30 Due: 03/01/31

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05685602 Org: User:
Start: 06/12/23 End: 04/30/26 Due: 04/30/27

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00956163 Org: User:
Start: 03/31/10 End: 05/31/14 Due: 05/31/15

Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia

Phase: N/A Priority: Normal
NCT ID: NCT02782949 Org: User:
Start: 04/04/17 End: 04/01/26 Due: 04/01/27

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06439836 Org: User:
Start: 05/05/25 End: 06/01/27 Due: 06/01/28

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase: N/A Priority: Normal
NCT ID: NCT06948084 Org: User:
Start: 10/31/25 End: 02/28/26 Due: 02/28/27

Differential Influences of Integral and Incidental Emotion on Cancer-related Judgments and Decision Making

Phase: N/A Priority: Normal
NCT ID: NCT02829554 Org: User:
Start: 07/08/16 End: 05/15/20 Due: 05/15/21

Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia

Phase: N/A Priority: Normal
NCT ID: NCT00303823 Org: User:
Start: 09/30/05 End: 02/28/11 Due: 02/28/12

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05155046 Org: User:
Start: 08/31/22 End: 12/31/29 Due: 12/31/30

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT01362790 Org: User:
Start: 05/11/11 End: 08/07/17 Due: 08/07/18

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04759586 Org: User:
Start: 10/05/21 End: 12/31/27 Due: 12/31/28